TL;DR
Findings highlight the novelty of KYNU as a therapeutic target and support the development of KS79356 as a potential treatment strategy for TNBC progression and metastasis.
Butoconazole is repurposed as a novel allosteric inhibitor of glucose-regulated protein 78 (GRP78) for TNBC treatment and represents a promising lead compound for further development as a systemic anti-TNBC agent through formulation optimization.
Summary Triple-negative breast cancer (TNBC) lacks effective targeted therapies, and YTHDF proteins are frequently overexpressed in this malignancy, which correlates with adverse prognosis. Through high-throughput drug screening, we identify ellagic acid (EA) as a compound that binds to YTHDF proteins and disrupts thei...
GPX4 is identified as the principal mediator of MLN4924-induced ferroptosis and dual targeting of GPX4 transcription and activity represents a promising therapeutic strategy for GBM, establishing that dual targeting of GPX4 transcription and activity represents a promising therapeutic strategy.
Aliflorin suppresses BC progression by inhibiting the HINT2/NLRP3 signaling pathway, suggesting HINT2 is a viable biomarker and Al a promising therapeutic agent for BC treatment.
Background Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and safer combination strategies with improved antitumor efficacy are still needed. Berberine (BBR), a natural isoquinoline alkaloid with multi-target pharmacological activity, and celecoxib (CXB), a selective cyclooxygenas...
A novel METTL3/ELF1/GPX4 axis through which METTL3 promotes TNBC growth by regulating oxidative stress and ferroptosis-related markers is suggested, providing a basis for further investigation of this pathway in the context of TNBC biology and therapeutic development.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
